Imran has served as Chief Technology Officer of Kimia Therapeutics since March 2025, leading development of Kimia's ATLAS platform for drug discovery. He brings to Kimia nearly 20 years of experience at the interface among chemistry, biology, and machine learning.

Before Kimia, he was most recently Senior Vice President of AI and Digital Sciences at Recursion, a pioneering leader in AI-enabled drug discovery and development. At Recursion, he built and led the data science and machine learning team that spanned platform development through therapeutic discovery to transform how drugs can be discovered using high-dimensional biological data and AI, and was technical lead for Recursion’s M&A and partnering efforts.

Prior to leading Recursion’s work in applying machine learning to biology and chemistry, Imran served as the first chief scientific officer at Freenome, leading the development of machine-learning-guided diagnostics for the early detection of cancer based on plasma multi-omics; and in roles of increasing responsibility at Counsyl (acquired by Myriad Genetics), pioneering the application of next-generation sequencing and computational methods to scale screening for Mendelian genetic disorders.

He earned his Ph.D in computer science from Stanford University, where in his thesis work he developed some of the first applications of GPU technology to scale machine learning in chemistry for drug discovery under the supervision of Drs. Vijay Pande and Daphne Koller, and his undergraduate degree in Electrical Engineering and Computer Science from UC Berkeley. He is the author of over 35 peer-reviewed articles, including in venues such as the Journal of the American Medical Association and Nature Genetics, and over 30 patents and patent applications.